Published July 2026 | Practical guidance for medical-device founders, QA/RA leaders, software teams, and AI governance owners. ISO 42001 vs ISO 13485 is not a choice between two competing quality standards. ISO 13485:2016 is the regulated medical-device quality management system backbone. ISO/IEC 42001:2023 is an organization-wide artificial intelligence management system standard that adds governance for … Read more
The RPM Cybersecurity Shift: Navigating New FDA Mandates and Software Supply Chain Transparency in 2026 A Senior Cybersecurity Architect’s Field Guide — Because “We Think We’re Covered” Is No Longer Good Enough May 2026 | 30-minute read | Written for C-Suite, Regulatory Affairs, and QA Leadership 📋 Table of Contents The Confidence Paradox: Why 90% … Read more
QMSR Transition: Harmonizing FDA 21 CFR 820 with ISO 13485:2016 — Post-Implementation Guide 2026 A post-implementation compliance and inspection readiness guide for medical device manufacturers — April 2026 Updated April 2026 | 18-minute read | FDA QMSR, ISO 13485:2016, CP 7382.850, ISO 14971 risk management Table of Contents The Day the QSR Died — How … Read more
The AI Drug Combination Discovery: 2026 Pharma Leader’s Guide provides an in-depth overview of the transformative impact of artificial intelligence on pharmaceutical development. With advancements in AI drug combination discovery, particularly through machine learning in pharma, the guide highlights the importance of computational drug combinations for optimising therapeutic efficacy. The incorporation of graph neural network drug synergy and digital twin pharma technologies facilitates enhanced drug synergy prediction AI, paving the way for innovative AI-driven combination therapy approaches. Furthermore, the exploration of quantum-classical hybrid drug discovery and multimodal AI pharma underscores the future of AI oncology drug combinations, positioning stakeholders to remain competitive in the evolving landscape.
The EU MedTech Innovation Pressure: Navigating 2026 “Crunch” and EY-DG SANTE Findings For years, the European Union was the global launchpad for EU MedTech Innovation, but recent data suggests a pivotal identity crisis is looming. A “CE Mark” was often the first major milestone for a startup before tackling the FDA. However, the tide has … Read more
